Antonio D'Alessio

26PUBLICATIONS
186CO-AUTHORS
Innate immunityPredictive and prognostic markersHaematological tumoursTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Oct 06, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Bernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio

|Sep 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.

Alessio Cortellini, Valentina Santo, Leonardo Brunetti

|Apr 09, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.

Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner

|Jan 10, 2025
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer.

David J Pinato, Pasquale Lombardi, Antonio D'Alessio

|Nov 04, 2024
New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.

Ezequiel Mauro, Manuel Rodríguez-Perálvarez, Antonio D'Alessio

|Apr 05, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.

David J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi

Pageof 5

Frequent Collaborators

15 joint publications

Lorenza Rimassa

13 joint publications

David James Pinato

11 joint publications

Nicola Personeni

7 joint publications

Antonella Cammarota